TY - JOUR T1 - Factors affecting COVID-19 outcomes in cancer patients: A first report from Guy’s Cancer Centre in London JF - medRxiv DO - 10.1101/2020.05.12.20094219 SP - 2020.05.12.20094219 AU - B Russell AU - C Moss AU - S Papa AU - S Irshad AU - P Ross AU - J Spicer AU - S Kordasti AU - D Crawley AU - H Wylie AU - F Cahill AU - A Haire AU - K Zaki AU - F Rahman AU - A Sita-Lumsden AU - D Josephs AU - C Harrison AU - A Rigg AU - R Sullivan AU - S Dolly AU - M Van Hemelrijck Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/19/2020.05.12.20094219.abstract N2 - Background There is insufficient evidence to support clinical decision-making for oncology patients diagnosed with COVID-19 due to the lack of large studies.Methods We used data from a large UK Cancer Centre to assess demographic/clinical characteristics of 106 cancer patients with a confirmed COVID-19 diagnosis between 29 February-15 April 2020. Logistic/Cox proportional hazards models were used to identify which demographic and/or clinical characteristics were associated with COVID-19 severity/death.Results 87 (82%) presented with mild/moderate COVID-19 and 19(18%) with severe disease. Age, sex, ethnicity, SES, and current cancer treatment were not associated with COVID-19 severity. Initial diagnosis of cancer >24m before COVID-19 (OR:3.01 (95%CI: 1.02-8.58)), presenting with fever, dyspnoea, gastro-intestinal symptoms, or higher levels of CRP and ferritin were linked with greater COVID-19 severity. During median follow-up of 17.5d, 14 patients had died of COVID-19(13%).Conclusions Low SES, hypertension and non-malignant lung disease were common in cancer patients with COVID-19. A longer-established diagnosis of cancer was associated with increasing severity of infection, possibly reflecting effects of more advanced malignant disease on impact of this infection. Advanced age and comorbidities may be associated with an increased risk of COVID-19-related death in cancer patients, as has been reported for general populations without cancer.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialData was collected from Guy's Cancer Cohort which is a research ethics committee approved research database (Reference number: 18/NW/0297) of all routinely collected clinical data of cancer patients at Guy’s and St Thomas’ NHS Foundation Trust (GSTT)Funding StatementThis project was made possible by funding from the GSTT Cancer FundAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData can be requested by contacting charlotte.moss{at}kcl.ac.uk ER -